Home
Services
Our Team
Hot Topics/News
Philosophy
Testimonials
Contact Us
Site Map
|
home
 hot topics/news |
AACC Los Angeles, CA
DNA Bridges®, Inc. is presenting the following sessions at the AACC
annual meeting in Los Angeles, CA
July 27-28, 2004
http://www.aaccdirect.org/AM/AMProduct.aspx?ID=2861
Chair: Eileen Gorman, Ph.D., CEO,
DNA Bridges, Inc.
Leader: Eileen G Gorman, PhD, DNA Bridges, Inc., Wilmington, DE
Barbara Handelin, PhD, Kenna Technologies, West Chester, PA
Steven Peckman, Univ. of California, Los Angeles
Level: Intermediate
CE Credit: 1.5
Intended Audience: This session is intended for laboratory
directors, pathologists, clinical chemists, pharmaceutical assay
developers, diagnostic industry managers and scientists.
Overview: As new markers are developed, laboratories are called
upon to evaluate them and their potential contribution to clinical
practice. As a result, knowledge of the Institutional Review Board
(IRB) process is key to participating in new marker development
and validation. The session focuses on laboratory perspectives of
key factors, including which representatives should be involved,
the advantages and disadvantages of various study designs, and
what studies may be considered exempt by the IRB. A case study
will be presented.
Expected Outcomes: After this session, participants will be able
to: 1) describe the key representatives required for the
institutional review board; 2) identify challenges in study design
that can impact the time required to obtain the study data; and 3)
explain what types of studies may be exempt from the IRB
requirements.
Tuesday, July 27, 2004
http://www.aaccdirect.org/AM/AMProduct.aspx?ID=3013
Tuesday, July 27 7:00 AM -
8:30 AM
4329 Interrelationships Between Drug Discovery, Development and
New Clinical Markers
Tuesday, July 27 12:15 PM -
1:45 PM
5329 Interrelationships Between Drug Discovery, Development and
New Clinical Markers
Presenter: Eileen G Gorman, PhD,
DNA Bridges, Inc., Wilmington, DE
Intended Audience: This session is intended for lab directors,
clinical chemists, IVD industrial managers and scientists.
Overview: More and more new clinical markers develop as a result
of drug discovery efforts. Relationships between drug development
and clinical markers will be explored. Case studies of clinical
markers coupled with therapeutics will be explored. Examples at
various stages of development and the impact on the laboratory
will be discussed.
Expected Outcomes: Describe the critical link between new drug
development and new marker development. Participants will also
able to evaluate the potential time for commercialization of new
markers related to new drugs being developed and summarize the
goals for their organization to respond to the new wave of new
drug related markers being developed.
2413 Cancer Screening Tests: More
Complexity Amid Large Test Volumes
Wednesday, July 28 2:00 PM - 5:45 PM
http://www.aaccdirect.org/AM/AMProduct.aspx?ID=3061
Leader: Barbara Handelin,
PhD, Kenna Technologies, West Chester, PA
Tony Shuber, EXACT Sciences Corp., Marlborough, MA
Eileen G Gorman, PhD, DNA Bridges, Inc., Wilmington, DE
Glenn Miller, PhD, Genzyme Genetics, Westborough, MA
Level:Intermediate
CE Credit: 3.5
Intended Audience: This session is intended for laboratory
directors, clinical and molecular pathologists, and clinical
chemists.
Overview: New cancer screening tests, expected to be performed on
millions of samples, will increasingly require the analysis of
complex genetic profiles (many mutations or gene expressions).
This session will discuss the complexity of the technology
combined with its complexity in interpretation, using PreGen Plus,
a new colorectal screening test, as an example. Solutions by
automation, interpretation software and the opportunity for
laboratory clinicians to play an important role in patient
management will also be presented.
Expected Outcomes: After this session, participants will be able
to: 1) describe why complex genetic profiling is critical in
current and future cancer screening tests; 2) identify the
specific technical challenges of new cancer tests; 3) identify the
specific information and interpretation challenges of new cancer
tests; and 4) define appropriate solutions (current and future)
for these technical and IT challenges.
|
